Replies to post #213755 on Biotech Values

[DewDiligence]

Curious that ICPT is being punished twice for essentially the same news as what was posted two weeks ago (#msg-134545079).

I'm not complaining, however, since I think Ocaliva is a bad drug that probably won't be approved for NASH.

[DewDiligence]

ICPT attempt at damage control fails to lift stock:

https://finance.yahoo.com/news/intercept-statement-regarding-ocaliva-obeticholic-110500499.html

No matter how you slice it, Ocaliva is a bad drug.